ReSynapse Therapeutics
Novel Multi-Target Neuropsychiatric Drugs via Computational Drug Design
Company Overview
Snapshot
Founded in December 2024 by Dorit Cohen Carmon, ReSynapse Therapeutics operates with 1–10 employees. The company has secured non-dilutive grants, validating its approach in developing novel neuropsychiatric drugs.
Business overview
ReSynapse Therapeutics is a biotechnology company focused on developing selective multi-target small molecules for treatment-resistant depression. The company utilizes systematic computational drug design to identify compounds that precisely modulate multiple serotonin receptors simultaneously. Its approach combines validated receptor biology with proprietary computational methodologies to enhance efficacy and safety, serving the health tech and life sciences sectors, particularly in drug discovery and development for pharmaceuticals.
Log in to access full profile ›Company Intelligence Q&A
- What is ReSynapse Therapeutics' primary focus?
- ReSynapse Therapeutics is focused on developing selective multi-target small molecules for treatment-resistant depression, utilizing computational drug design to modulate serotonin receptors.
- When was ReSynapse Therapeutics founded?
- ReSynapse Therapeutics was founded in December 2024.
- Who is the founder of ReSynapse Therapeutics?
- Dorit Cohen Carmon is the founder of ReSynapse Therapeutics.
- What is ReSynapse Therapeutics' current product development stage?
- ReSynapse Therapeutics is currently in the R&D stage, with in-vitro proof-of-concept validation in progress and plans for IP filing in Q1 2026.
- What market does ReSynapse Therapeutics target?
- ReSynapse Therapeutics targets the treatment-resistant depression market, which is estimated at $1.9 billion, with potential scalability to other CNS indications like anxiety and PTSD.